Olympus Corporation Signs Exclusive Global Distribution Agreement with EndoRobotics

Ltd. on May 4, 2026. Under the agreement, robot-assisted technologies manufactured by EndoRobotics will be distributed globally by Olympus exclusively as part of its EndoTherapy portfolio. Olympus aims to expand patient access to endoscopic procedures for treatment of early-stage cancers and precancerous lesions of the GI tract.

The collaboration will drive broader adoption of advanced endoscopic procedures such as endoscopic submucosal dissection (ESD). ESD allows physicians to remove diseased tissue without resecting the organ. EndoRobotics technologies can enhance precision, control, and efficiency in complex procedures such as ESD.

These technologies play an increasingly important role in supporting consistent outcomes, particularly as the global incidence of GI cancers continues to rise. " Callaghan added, "This collaboration supports our strategy to broaden adoption of advanced treatment options such as ESD.

Olympus Corporation is a global MedTech company. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. " Kim and Hong continued, "To achieve this, we are proud to partner with Olympus Corporation, a leading endoscopy company.

EndoRobotics is dedicated to advancing minimally invasive treatments for gastrointestinal diseases through the development of next-generation endoscopic intervention robotics. U.S. Additional details regarding availability and regional product launches will be shared in accordance with regulatory requirements and local market considerations.

The agreement reflects Olympus' approach to advancing endoluminal robotics, bringing new technologies that support complex endoscopic therapy to global markets today, while continuing to invest in longer-term platform innovations designed to further transform endoscopy-enabled care, Benzinga reported.